Extramedullary Orbital Granulocytic Sarcoma Without Bone Marrow Involvement: A Report of Two Cases

Isik P., Tavil B., Tunc B., Yarali N., Demir A., Cetin M.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.28, no.1, pp.65-70, 2011 (SCI-Expanded) identifier identifier identifier


The authors present herein 2 extramedullary orbital granulocytic sarcoma (GS) cases without bone marrow involvement in view of their rarity and also to reevaluate the treatment approach in this disease. Seven days of high-dose methyl prednisolone (HDMP) treatment (3 days 30 mg/kg/day and 4 days 20 mg/kg/day) was administered initially, and subsequently Acute Myeloid Leukaemia-Berlin Frankfurt Munster (AML-BFM) 2004 treatment protocol was continued for 2 cases. Eye findings of the cases resolved considerably with HDMP treatment. They have still been under systemic chemotherapy without any complication for 1 year. Thus, early diagnosis and AML-targeted intensive chemotherapy improve the prognosis of GS even if there is no bone marrow involvement.